View:
Download DOC
Download PDF
Download XLS
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 6-K
 
 
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
Date of Report: November 4, 2022
 
Commission File Number: 001-39307
 
 

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
 
 
 
2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F  ☒            Form 40-F  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
Legend Biotech Announces Participation in Upcoming Investor Conferences

On November 4, 2022, Legend Biotech Corporation (“Legend Biotech”) issued a press release announcing its participation in upcoming investor conferences.

The press release announcing the upcoming investor conferences is attached to this Form as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Form 6-K, excluding Exhibit 99.1, is hereby incorporated by reference into Legend Biotech’s Registration Statements on Form F-3 (Registration Nos. 333-257625 and 333-257609) and Legend Biotech’s Registration Statement on Form S-8 (Registration No. 333-239478).


EXHIBIT INDEX

Exhibit
 Title


99.1 Press Release, dated November 4, 2022
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
LEGEND BIOTECH CORPORATION
 
 
 
Date: November 4, 2022
By:
/s/ Ying Huang
 
Name:
Ying Huang, Ph.D.
 
Title:
Chief Executive Officer

Exhibit 99.1

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--November 4, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: BMO Biopharma Spotlight Series: Oncology Day (Virtual)
Fireside Chat Date & Time: Wednesday, November 9, 2022 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Cowen 6th Annual IO Next Summit (Virtual)
Fireside Chat Date & Time: Friday, November 11, 2022 at 1:10pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: JP Morgan Equity Opportunities Forum
Location: Miami, Florida
Date: Monday, November 14, 2022

Event: Jefferies London Healthcare Conference
Location: London
Fireside Chat Date & Time: Thursday, November 17, 2022 at 2:40pm GMT
Presenter: Ying Huang, Ph.D., CEO

Event: Piper 34th Annual Healthcare Conference
Location: New York, New York
Fireside Chat Date & Time: Tuesday, November 29, 2022 at 3:00pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Evercore ISI 5th Annual HealthCONx Conference (Virtual)
Fireside Chat Date & Time: Wednesday, November 30, 2022 at 9:40am ET
Presenter: Ying Huang, Ph.D., CEO

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Contacts

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025